TGFB1 and liver cancer: NK-92 cells engineered with TGF-β/NKG2D CAR released a higher amount of IFNγ, showed a lytic capacity, inhibited Treg differentiation, exhibited an enhanced chemoattraction to TGF-b-releasing tumor cells, and inhibited tumor growth in a xenograft model of liver cancer [125].